|
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada |
Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thrombosis and Haemostasis 2010; 104(4): 760-770 Indexing Status Subject indexing assigned by NLM MeSH Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis /methods; Enoxaparin /economics /therapeutic use; Follow-Up Studies; Humans; Morpholines /economics /therapeutic use; Postoperative Complications; Quality of Life; Rivaroxaban; Sensitivity and Specificity; Thiophenes /economics /therapeutic use; Venous Thromboembolism /etiology /prevention & control AccessionNumber 22010001954 Date bibliographic record published 04/05/2011 |
|
|
|